A detailed history of Morgan Stanley transactions in Chemomab Therapeutics Ltd. stock. As of the latest transaction made, Morgan Stanley holds 402,272 shares of CMMB stock, worth $663,748. This represents 0.0% of its overall portfolio holdings.

Number of Shares
402,272
Previous 7,200 5487.11%
Holding current value
$663,748
Previous $6,000 10416.67%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.93 - $2.46 $367,416 - $971,877
395,072 Added 5487.11%
402,272 $631,000
Q2 2024

Oct 17, 2024

BUY
$0.59 - $1.29 $2,597 - $5,679
4,403 Added 157.42%
7,200 $6,000
Q2 2024

Aug 14, 2024

BUY
$0.59 - $1.29 $2,597 - $5,679
4,403 Added 157.42%
7,200 $6,000
Q1 2024

Oct 17, 2024

SELL
$0.5 - $0.86 $2,201 - $3,786
-4,403 Reduced 61.15%
2,797 $2,000
Q1 2024

Aug 16, 2024

SELL
$0.5 - $0.86 $34,059 - $58,581
-68,118 Reduced 96.06%
2,797 $2,000
Q1 2024

May 15, 2024

SELL
$0.5 - $0.86 $34,059 - $58,581
-68,118 Reduced 96.06%
2,797 $2,000
Q4 2023

Aug 16, 2024

BUY
$0.45 - $0.9 $28,671 - $57,343
63,715 Added 884.93%
70,915 $36,000
Q4 2023

Feb 13, 2024

BUY
$0.45 - $0.9 $31,911 - $63,823
70,915 New
70,915 $36,000
Q2 2023

Aug 14, 2023

SELL
$1.0 - $1.84 $7,700 - $14,168
-7,700 Reduced 98.72%
100 $0
Q1 2023

May 15, 2023

BUY
$1.44 - $2.94 $1,728 - $3,528
1,200 Added 18.18%
7,800 $12,000
Q4 2022

Feb 14, 2023

BUY
$1.9 - $3.2 $760 - $1,280
400 Added 6.45%
6,600 $21,000
Q3 2022

Nov 14, 2022

BUY
$2.33 - $4.0 $1,409 - $2,420
605 Added 10.81%
6,200 $15,000
Q2 2022

Aug 15, 2022

BUY
$2.58 - $4.88 $14,435 - $27,303
5,595 New
5,595 $21,000
Q1 2022

May 13, 2022

SELL
$3.53 - $7.2 $41,099 - $83,829
-11,643 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$6.41 - $11.13 $74,022 - $128,529
11,548 Added 12155.79%
11,643 $80,000
Q3 2021

Nov 15, 2021

BUY
$11.08 - $19.17 $1,052 - $1,821
95 New
95 $1,000

Others Institutions Holding CMMB

About Chemomab Therapeutics Ltd.


  • Ticker CMMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,431,700
  • Market Cap $18.9M
  • Description
  • Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...
More about CMMB
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.